LBRX · Lb Pharmaceuticals Inc
Market Cap
$1.51B
Shares
32.26M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$25.21M
+60.1%
FY2025
Diluted EPS
-$3.13
+98.2%
FY2025
Operating Cash Flow
-$35.21M
+33.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $69.69M | $16.74M | $51.17M | |
| $25.44M | $13.66M | $13.66M | |
| — | $321K | $91K | |
| $95.14M | $30.4M | $64.83M | |
| $9.33M | $3.92M | $1.72M | |
| $9.45M | $5.2M | $1.73M | |
| -$85.68M | -$25.2M | -$63.1M | |
| $1000 | $1000 | $1000 | |
| -$85.69M | -$25.21M | -$63.1M | |
| -$60.51M | -$25.21K | -$63.1K | |
| -$85.5M | -$25.15M | -$63.27M | |
| USD/shares | $22.86 | -$3.13 | -$176.15 |
| USD/shares | $22.86 | -$3.13 | -$176.15 |
| shares | — | 8.05M | 358.23K |
| shares | — | 8.05M | 358.23K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 9 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Key facts
CIK
1691082
CUSIP
50180M108
13F (30d)
99 filings
99 filers
Visit website
Investor relations